中药高位结肠肠浴治疗重型肝炎39例临床观察

重型病毒性肝炎患者消化道症状明显．药物口服困难．以致中药复方难以发挥作用。笔者采用IMS-IOOA型结肠途径治疗机（结疗机）进行中药高位结肠肠浴．治疗39例重型病毒性肝炎患者．取得较好疗效。     

慢性乙型肝炎患者肝组织炎性活动程度与α-干扰素疗效的关系

目的 :探讨慢性乙型肝炎 (ChronichepatitisB ,CHB)患者肝组织炎性活动程度与α 干扰素 (α IFN )疗效的关系。方法 :对 84例使用赛诺金 (αlb IFN )的CHB患者治疗前肝活检组织进行炎症分级及Ishak计分 ,并与α IFN治疗后及停药 1年后复发情况作一对比分析。结果 :随着肝组织炎症分级进展 ,α IFN的完全应答率明显上升( χ2 =11 63 ;P <0 0 1)。停药 1年后不同炎症分级患者的HBV感染复发率并无差异。 8例完全应答者α IFN治疗结束时 ,肝组织Ishak计分自 12 8± 3 0降至 8 1± 2 8(t =3 2 4;P <0 0 1)。结论 :CHB肝组织炎症分级与α IFN近期疗效密切相关。α IFN完全应答者肝组织学状况明显改善     

病毒性肝炎特殊并发症2例

肝炎病毒可侵犯许多肝外组织器官，造成相应的病变。肝脏功能的异常，使体内物质代谢异常，亦可造成肝外组织器官病变。某些少见的肝外表现容易误诊、漏诊，临床医生应提高认识。     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

甲亢患者放射性131I治疗前后血浆LP(a)浓度的变化

目的　研究甲状腺激素对血浆脂蛋白 (a) [LP(a) ]浓度的影响。方法　采用ELISA法检测血浆LP(a)浓度 ,纵向观察 8例甲亢患者放射性13 1I治疗前后血浆LP(a)浓度的变化。我们测定下列 3种状态的LP(a)浓度 ,即治疗前甲亢状态 (H状态 )、丙基硫氧嘧啶治疗后的甲状腺功能呈基本正常状态 (E1状态 )和放射性13 1I治疗后甲状腺功能正常状态 (E2状态 )。结果　治疗前H状态血脂LP(a) ,TC ,HDL -C ,LDL -C ,apoA1和apoB浓度低于对照组 (P <0 .0 5 ) ;从H到E1,再到E2状态 ,LP(a)浓度逐渐升高 ,差异具有统计学意义 (P <0 .0 5～ 0 .0 1)。TC ,DL -C ,apoA1及apoB2亦有类似的变化 (P <0 .0 5～ 0 .0 1) ;治疗前后LP(a)的变化与FT3(r =- 0 .0 4 )和FT4 (r=- 0 .4 6 )的变化呈负相关 (P <0 .0 5 )。结论　甲状腺激素对LP(a)的代谢有调控作用。     

姜黄素对肝纤维化大鼠肝组织中核转录因子-кB及细胞外信号调节激酶-1mRNA表达的影响

目的 探讨核转录因子-кB (NF-кB )及细胞外信号调节激酶(ERK) mRNA在CCl4致实验性肝纤维化大鼠肝组织中的表达及姜黄素(CUR)对它们的影响.方法 建立CCl4致大鼠实验性肝纤维化的模型,用免疫组织化学法比较正常组、模型组以及CUR组的α平滑肌肌动蛋白(α-SMA)的表达,用RT-PCR法比较各组肝组织NF-кB以及ERK-1 mRNA的表达.结果 NF-кB mRNA 及ERK-1mRNA的表达: 正常组分别为0.317±0.035和0.434±0.067,模型组分别为1.219±0.158和0.944±0.151,CUR组分别为0.912±0.274和0.736±0.293,CUR组与模型组比较,P值均＜0.05,差异有统计学意义.α-SMA的表达:CUR组为4.327±2.064,模型组为6.784±2.158,正常组为0.943±0.371,CUR组与模型组比较,P值均＜0.05 ,差异有统计学意义.结论 CUR可能通过抑制α-SMA的表达,减弱NF-кB诱导的肝星状细胞的活化以及抑制ERK-1的促肝星状细胞的增殖,从而起到抗大鼠肝纤维化的作用.     

姜黄素对肝纤维化大鼠肝组织中NF-κB及ERK-1 mRNA表达的影响

目的 探讨核转录因子-κB(nuclear factor kappa B,NF-κB)及细胞外信号调节激酶(extracegular signal-reglulated kinase,ERK)mRNA在CCl4致实验性肝纤维化大鼠肝组织中的表达及姜黄素(curcumin,CUR)对它们的影响.方法 建立CCl4致大鼠实验性肝纤维化的模型,用免疫组化法比较正常组、模型组及CUR组的α平滑肌肌动蛋白(α-SMA)的表达,用RT-PCR法比较各组肝组织NF-κB及ERK-1 mRNA的表达.结果 模型组中,ERK-1及NF-κB mRNA的表达均增高,而CUR组α平滑肌肌动蛋白则较模型组低,NF-κB及ERK-1 mRNA的表达也降低.结论 CUR可能通过抑制α-SMA的表达,减弱NF-κB诱导的肝星状细胞的活化及抑制ERK-1促肝星状细胞的增殖,从而产生抗四氯化碳诱导的大鼠肝纤维化的作用.     

拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者的临床观察

目的:探讨拉米夫定(LAM)联合阿德福韦酯(AVD)治疗乙型肝炎肝硬化失代偿期的疗效、安全性。方法:选择2006年6月～2008年6月门诊和住院乙型肝炎肝硬化失代偿期患者93例,随机分为3组。A组单用LAM(100mg·d-1);B组采用ADV(10mg·d-1);C组采用ADV(10mg·d-1)、LAM(100mg·d-1)联合治疗;3组均治疗52周。结果:治疗52周时3组患者间ALT水平、HBeAg阳性患者血清转换率比较,差异均无统计学意义(P>0.05);C组患者HBVDNA水平达到检测水平以下的百分率与B组患者比较,有显著性差异(P<0.05);3组间肝功能Child-Pugh评分比较差异无统计学意义(P>0.05)。3组患者的基因型耐药率分别为21.9%(7/32)、0、0。结论:乙型肝炎肝硬化失代偿期采用LAM联合ADV治疗更安全有效。     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.